Gornitzky represented the underwriters, led by Ladenburg Thalmann, in Pluristem Therapeutics’ underwritten public offering of shares and warrants on the NASDAQ Capital Market and concurrent registered direct offering of its shares, raising USD 21 million.
Pluristem Therapeutics Inc. is a regenerative medicine company developing novel placenta-based cell therapy product candidates and is dually listed on the NASDAQ and the Tel Aviv Stock Exchange.
Ladenburg Thalmann & Co. Inc. acted as sole book running manager for the public offering and as placement agent for the registered direct offering. H.C. Wainwright & Co., acted as lead manager for the public offering and Maxim Group LLC and LifeSci Capital LLC acted as co-managers for the public offering.
The underwriters were represented by partners Chaim Friedland and Ari Fried along with associate Neta Peled.